Jab. You "get it" (not that I'm surprised) :) Those who claim that Rasuvo will take share from Otrexup by simply showing up are NOT seasoned business people. Naïve perhaps (or worse), but not seasoned business pros as yourself. Some inroads will be made over time, but those inroads won't be easy.
The last place you want to be as a competitor is second to market with a "vanilla" product that has NO pricing, user, or product benefits versus the first to market product leader. As you said, an over the counter device coupled with a generic drug doesn't create a compelling value proposition. And no, they can't price themselves into a "value" position either. Antares no co-pay strategy all but destroys that line of thinking except for a small (single digit) percentage of potential users.
News 
Market Data 
Discover 
AI
